Any current/future new fundraising through debt or equity?

There is no explicit mention of any ongoing or planned new fundraising through debt or equity in the provided transcript. The discussion about funding challenges mainly pertains to the pharma space, especially funding for Phase I/II molecules and smaller biotech customers facing slowdowns. Hikal management stated they are not deeply involved in Phase II, III funding challenges and did not indicate any need to raise funds currently. Capex plans are primarily funded through internal resources, with INR200 crores planned for the current year and INR500 crores CWIP ongoing. No indications or annou

Any current/future capex/capital investment/strategic investment?

Hikal Limited is undertaking significant capital expenditure (capex), targeting INR 200 crores in the current financial year, with about INR 170 crores already incurred and the balance expected soon. A major ongoing project is the commissioning of a new multipurpose plant at Panoli, part of an INR 500 crores investment MoU signed with the Gujarat government. This new plant is anticipated to be operational by Q1 or Q2 of the coming quarters and will primarily cater to crop protection with a focus on backward integration. Future capex beyond the current year is expected to be moderate, with INR

Future growth expectations in sales/revenue/volumes?

Revenue and margins expected to pick up from the second half of FY '25, reaching pre-COVID levels. Pharma business volumes and margins are recovering, with a full revival anticipated by H2 FY '25. Crop Protection currently faces destocking, expected to normalize and improve from Q3 or Q4 of the next financial year (FY '25). Medium to long-term industry fundamentals remain intact despite short-term challenges. Double-digit revenue growth expected post-normalization, targeting INR 3,000+ crores by FY '27–'28 from INR 2,000+ crores currently. Focus on growing CDMO business significantly

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal expects revenue and margins to normalize and improve to pre-COVID levels by the second half of FY '25. Growth driven by revival in Pharma (API and CDMO) and Crop Protection segments, with volumes and margins recovering. CDMO business share is targeted to increase significantly over the next 3-4 years, supporting margin expansion. EBITDA margins are expected to improve from current levels (~14-15%) back to earlier steady-state levels around 18-19%, possibly higher. Operating leverage from recent capex (~INR500-700 crores) and new multipurpose facilities commissioning will support margin e

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in specific figures. However, it notes a "robust pipeline" of projects in the CDMO space, indicating healthy ongoing and potential future orders. There are "several projects under advanced stage of discussion with existing innovator customers as well as new customers" in the Crop Protection business, signaling strong order inflow prospects. Post-incident reassurances leading to onboarding of new customers suggest an increase in the order book. In Animal Health, discussions are underway with several

HikalQ3 FY24Pharmaceuticals & Biotechnology

Hikal Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 63.3Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Revenue and margins expected to pick up from the second half of FY '25, reaching pre-COVID levels.
Pharma business volumes and margins are recovering, with a full revival anticipated by H2 FY '25.
Crop Protection currently faces destocking, expected to normalize and improve from Q3 or Q4 of the next financial year (FY '25).
Medium to long-term industry fundamentals remain intact despite short-term challenges.
Double-digit revenue growth expected post-normalization, targeting INR 3,000+ crores by FY '27–'28 from INR 2,000+ crores currently.
Focus on growing CDMO business significantly, with a rising share in overall revenue expected over the next 3-4 years.
Animal Health segment projected to contribute INR 200-300 crore revenue within 3-4 years, with ramp-up beginning FY '25.
Continuous new product launches in Pharma (3-4 products annually) supporting growth.
Capex of INR 200 crore planned for FY '24, aiding capacity expansion and future growth.

Margin guidance

Category 1

Hikal expects revenue and margins to normalize and improve to pre-COVID levels by the second half of FY '25.
Growth driven by revival in Pharma (API and CDMO) and Crop Protection segments, with volumes and margins recovering.
CDMO business share is targeted to increase significantly over the next 3-4 years, supporting margin expansion.
EBITDA margins are expected to improve from current levels (~14-15%) back to earlier steady-state levels around 18-19%, possibly higher.
Operating leverage from recent capex (~INR500-700 crores) and new multipurpose facilities commissioning will support margin expansion.
Medium to long-term outlook is positive with potential double-digit revenue growth and margin expansion up to 23-25% EBITDA over next 3-4 years.
Animal Health business and new projects expected to contribute to future growth and profitability.
Overall, Hikal aims for significant earnings growth and margin improvement by FY '27-'28 aligned with industry normalization and capex ramp-up.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any ongoing or planned new fundraising through debt or equity in the provided transcript.
The discussion about funding challenges mainly pertains to the pharma space, especially funding for Phase I/II molecules and smaller biotech customers facing slowdowns.
Hikal management stated they are not deeply involved in Phase II, III funding challenges and did not indicate any need to raise funds currently.
Capex plans are primarily funded through internal resources, with INR200 crores planned for the current year and INR500 crores CWIP ongoing.
No indications or announcements related to new equity or debt fundraising were discussed during the Q&A or management commentary.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in specific figures.
However, it notes a "robust pipeline" of projects in the CDMO space, indicating healthy ongoing and potential future orders.
There are "several projects under advanced stage of discussion with existing innovator customers as well as new customers" in the Crop Protection business, signaling strong order inflow prospects.
Post-incident reassurances leading to onboarding of new customers suggest an increase in the order book.
In Animal Health, discussions are underway with several customers at various stages, showing potential future orders.
Overall, continuous discussions with existing and potential clients imply a steady and growing order book aligned with the company’s growth plans.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes

Hikal Limited is undertaking significant capital expenditure (capex), targeting INR 200 crores in the current financial year, with about INR 170 crores already incurred and the balance expected soon.
A major ongoing project is the commissioning of a new multipurpose plant at Panoli, part of an INR 500 crores investment MoU signed with the Gujarat government.
This new plant is anticipated to be operational by Q1 or Q2 of the coming quarters and will primarily cater to crop protection with a focus on backward integration.
Future capex beyond the current year is expected to be moderate, with INR 30-40 crores planned in the next quarter.
The company aims to fully capitalize and operationalize the INR 500 crores CWIP with total capex over two years expected to be around INR 700 crores.
These investments are strategic, aimed at growing the CDMO business and enhancing long-term capacities across pharma, animal health, and crop protection segments.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHikal

Rev 3Mar 1

See where Hikal sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →